Revance Therapeutics reported $449.74M in Debt for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Debt Change
Abbvie ABBV:US $ 73474M 3210M
Aerie Pharmaceuticals AERI:US $ 311.68M 77.15M
ALKERMES ALKS:US $ 295.17M 0.63M
Bristol Myers Squibb BMY:US $ 44972M 419M
Cara Therapeutics CARA:US $ 0 0
Coherus Biosciences CHRS:US $ 420.46M 10.94M
Eli Lilly And LLY:US $ 16508.8M 375.9M
Endo International Ordinary Shares ENDP:US $ 8090.62M 183.92M
Horizon Pharma HZNP:US $ 2568.74M 2.49M
JAZZ PHA JAZZ:US $ 6023.87M 32.75M
Johnson & Johnson JNJ:US $ 33148M 603M
Merk MRK:US $ 31794M 1308M
Neurocrine Biosciences NBIX:US $ 377.7M 42.6M
Pacira Pharmaceuticals PCRX:US $ 923.42M 125.81M
Procter & Gamble PG:US $ 33669M 1984M
Revance Therapeutics RVNC:US $ 449.74M 169.1M
Supernus Pharmaceuticals SUPN:US $ 400.38M 21.13M
Teva Pharmaceutical Industries TEVA:US $ 22917M 126M